A share price of Zymeworks BC Inc [ZYME] is currently trading at $26.71, down -2.27%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ZYME shares have gain 12.13% over the last week, with a monthly amount glided 37.82%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright upgraded its rating to Buy on October 14, 2025, and kept the price target unchanged to $26. On October 10, 2025, B. Riley Securities initiated with a Buy rating and assigned a price target of $30 on the stock. TD Cowen started tracking the stock assigning a Buy rating. JP Morgan upgraded its rating to an Overweight but $18 remained the price target by the analyst firm on December 16, 2024. Leerink Partners upgraded its rating to Outperform for this stock on November 07, 2024, and upped its price target to $25. In a note dated November 01, 2024, Wells Fargo downgraded an Equal Weight rating on this stock but restated the target price of $12.
Zymeworks BC Inc experienced fluctuations in its stock price throughout the past year between $9.03 and $28.49. Currently, Wall Street analysts expect the stock to reach $32 within the next 12 months. Zymeworks BC Inc [NASDAQ: ZYME] shares were valued at $26.71 at the most recent close of the market. An investor can expect a potential return of 19.81% based on the average ZYME price forecast.
Analyzing the ZYME fundamentals
Trailing Twelve Months sales for Zymeworks BC Inc [NASDAQ:ZYME] were 134.48M which represents 72.59% growth. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -207.35%, Pretax Profit Margin comes in at -171.28%, and Net Profit Margin reading is -183.83%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.24 and Total Capital is -0.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 26.18 points at the first support level, and at 25.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 27.47, and for the 2nd resistance point, it is at 28.22.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Zymeworks BC Inc [NASDAQ:ZYME] is 6.94. Further, the Quick Ratio stands at 6.94, while the Cash Ratio is 1.54. Considering the valuation of this stock, the price to sales ratio is 14.98, the price to book ratio is 6.32.
Transactions by insiders
Recent insider trading involved Derek John Michael Miller, Former Director, that happened on Nov 24 ’25 when 0.12 million shares were purchased. Former Director, Neil Gallagher completed a deal on Nov 21 ’25 to buy 0.1 million shares. Meanwhile, Director EcoR1 Capital, LLC bought 49502.0 shares on May 15 ’25.
